LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

LYNPARZA’s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience August 17, 2017 KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc. (NYSE:MRK), known as MSD outside the […]